| Name | Title | Contact Details |
|---|
TYME is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles.
At BioNTech we believe that every cancer patient’s treatment should be individualized. Our vision is to provide patient-specific immunotherapies worldwide.
With its acquisition of Spyre Therapeutics, Aeglea is shifting its disease focus to inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD.
Ikaria is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
CombiMatrix Corporation is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.